New JAK3 Inhibitor ZL-82 Shows Promise for Rheumatoid Arthritis Treatment

A Phase I clinical trial has completed testing of ZL-82, a novel oral medication targeting rheumatoid arthritis and inflammatory bowel disease through selective JAK3 inhibition. The study aimed to evaluate safety, tolerability, and pharmacokinetics of single and multiple doses in healthy adults.

The trial enrolled 69 participants who received ZL-82 at three dose levels: 12.5mg, 25mg, and 50mg. Researchers examined how the body processes the drug, whether food affects absorption, and monitored for adverse effects during the treatment period from April 2023 to June 2024.

ZL-82 represents a significant advancement over existing JAK inhibitors like tofacitinib. Laboratory testing showed ZL-82 inhibits JAK3 with exceptional selectivity, demonstrating 100-fold and 20-fold better specificity compared to tofacitinib for JAK1 and JAK2 respectively. This precision targeting could minimize cardiovascular and other side effects associated with broader JAK inhibition.

Preclinical studies in animal models showed dose-dependent reduction in joint swelling at doses ranging from 25-100 mg/kg. The drug works by blocking inflammatory cytokine pathways that drive autoimmune responses in rheumatoid arthritis and inflammatory bowel disease.

While specific results haven't been published, the trial's completion marks an important step toward developing safer anti-inflammatory treatments. The selective JAK3 inhibition approach could offer patients effective symptom relief with reduced risk of cardiovascular complications that have limited other JAK inhibitors.